


Cevimeline

Cat. No.:	HY-70020
CAS No.:	107233-08-9
Molecular Formula:	C ₁₀ H ₁₇ NOS
Molecular Weight:	199.31
Target:	mAChR
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Cevimeline (AF-102B) is a quinuclidine derivative of acetylcholine and a selective and orally active muscarinic M1 and M3 receptor agonist. Cevimeline stimulates secretion by the salivary glands and can be used as a sialogogue for xerostomia ^{[1][2]} ^{[3][4]} . Cevimeline can cross the blood-brain barrier (BBB) ^[5] .								
IC₅₀ & Target	Muscarinic M1 and M3 receptor ^[1]								
In Vitro	In digested parotid cells, Cevimeline (0.1-100 μM) increases the intracellular Ca ²⁺ concentration ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	Cevimeline (0.008-0.016 mg/kg; intraperitoneal injection; male Wistar rats) treatment shows slowly increasing and lasting salivation, and increased blood flow increment in the parotid gland and pressor response. Cevimeline inhibits angiotensin II-induced water intake and neuronal activity in the subfornical organ at 0.016 mg/kg ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>Male Wistar rats (8-week-old) injected with angiotensin-II^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0.008 mg/kg, 0.016 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection</td> </tr> <tr> <td>Result:</td> <td>Showed slowly increasing and lasting salivation, and increased blood flow increment in the parotid gland and pressor response.</td> </tr> </table>	Animal Model:	Male Wistar rats (8-week-old) injected with angiotensin-II ^[1]	Dosage:	0.008 mg/kg, 0.016 mg/kg	Administration:	Intraperitoneal injection	Result:	Showed slowly increasing and lasting salivation, and increased blood flow increment in the parotid gland and pressor response.
Animal Model:	Male Wistar rats (8-week-old) injected with angiotensin-II ^[1]								
Dosage:	0.008 mg/kg, 0.016 mg/kg								
Administration:	Intraperitoneal injection								
Result:	Showed slowly increasing and lasting salivation, and increased blood flow increment in the parotid gland and pressor response.								

REFERENCES

[1]. Witsell DL, et al. Effectiveness of cevimeline to improve oral health in patients with postradiation xerostomia. *Head Neck*. 2012 Aug;34(8):1136-42. doi: 10.1002/hed.21894. Epub 2012 Jan 9.

[2]. Ono K, et al. Distinct effects of cevimeline and pilocarpine on salivary mechanisms, cardiovascular response and thirst sensation in rats. *Arch Oral Biol*. 2012 Apr;57(4):421-8. Epub 2011 Nov 17.

[3]. Kondo Y, et al. Cevimeline-induced monophasic salivation from the mouse submandibular gland: decreased Na⁺ content in saliva results from specific and early activation of Na⁺/H⁺ exchange. *J Pharmacol Exp Ther*. 2011 Apr;337(1):267-74. Epub 2011 Jan 14.

[4]. Voskoboynik B, et al. Cevimeline (Evoxac) overdose. J Med Toxicol. 2011 Mar;7(1):57-9.

[5]. Mitoh Y, et al. Effects of cevimeline on excitability of parasympathetic preganglionic neurons in the superior salivatory nucleus of rats. Auton Neurosci. 2017 Sep;206:1-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA